Brand Name(s): Amaryl
CAS nº: 93479-97-1
(glye’ me pye ride)
About Glimepiride
This new site is dedicated exclusively to glimepiride, the generic name given to its brand equivalent Amaryl® which is marketed by Aventis.
It offers you the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about glimepiride, as well as take part in our open discussion forum by sharing your own knowledge and experiences with people who are using this medication.
This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total glimepiride experience!
Why is this medication prescribed?
Glimepiride is an oral diabetes medicine that helps control blood sugar levels. This medication helps your body respond better to insulin produced by your pancreas.
Glimepiride is used together with diet and exercise to treat type 2 (non-insulin dependent) diabetes. When required, other diabetes medicines are sometimes used in combination with glimepiride.
Latest News
Effect of diabetes drugs
In a 18-month study comparing the effects of two diabetes drugs in patients with type 2 diabetes,...
[more]New data showed Actos prevented progression of atherosclerotic plaque volume in patients
Data expands body of evidence in high risk population using IVUS, a unique marker for coronary...
[more]Expanded Labelling for Januvia Approved by European Commission
Merck Sharp & Dohme (MSD) today announced that the European Commission has approved 'Januvia'...
[more]Novo Nordisk Reports Results From Liraglutide Study
Danish drugmaker Novo Nordisk’s final Phase III study of liraglutide, the once-daily human GLP-1...
[more]Pioglitazone slowed progression of carotid artery intima-media thickness compared with glimepiride
In a randomized, double-blind, comparator-controlled, multicenter trial of 462 type 2 diabetes...
[more]